glp 1 drugs breastfeeding GLP-1s and — Bridges Lactation Breastfeeding and GLP-1 Medications: Safety

Drug Development Research

Additionally, patients receiving GLP-1 medications often have metabolic conditions that independently affect cancer risk, making it challenging to isolate drug effects

Paid subscribers received the below on July 11th 2023.1 Introduction View & Download a spreadsheet of the Thematic Equity Basket, including tickers & weightings, which is discussed in this article here There are 5 FDA approved drugs for weight loss, currently: orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide

Relevant financial disclosures: None

These GLP-1 receptor agonists can be categorized as either short-acting compounds, which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compounds (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose